RxDoctor Payments Data

Sandy Khin, MD

Internal Medicine · Lakeland, FLNPI 1689923112

Payments from drug & device makers

$433in general payments, 2019–2025

Across 21 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$238
  • Novo Nordisk$54
  • Abiomed$33
  • Pfizer$29
  • Dexcom, Inc.$25
  • Lilly USA, LLC$21
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$41997%
  • Education$143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)11$238
Novo Nordisk3$54
Abiomed1$33
Pfizer2$29
Dexcom, Inc.1$25
Lilly USA, LLC1$21
Boston Scientific1$19
Amgen1$14

How this compares

$433 in reported general payments places this provider in the 50th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$54,220
Medicare patients
115
Services billed
1,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide120$135,494
JardianceEmpagliflozin85$104,632
EliquisApixaban66$85,172
MounjaroTirzepatide47$52,861
RybelsusSemaglutide27$42,935
FarxigaDapagliflozin Propanediol20$21,032
XareltoRivaroxaban21$20,484
Budesonide ErBudesonide11$17,274
TrulicityDulaglutide16$16,632
Praluent PenAlirocumab13$15,589
Lantus SolostarInsulin Glargine,hum.Rec.Anlog65$14,768
Rosuvastatin Calcium601$11,972
LinzessLinaclotide11$7,911
JanuviaSitagliptin Phosphate11$6,785
Ezetimibe237$6,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$54$178,429147 claims
PfizerEliquis$29$85,17266 claims
Lilly USA, LLCMounjaro, Trulicity$21$69,49363 claims
AbbVieLinzess$238$7,91111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →